0
0
WASHINGTON — The U.S. Food and Drug Administration (FDA) announced a landmark regulatory decision on June 30, 2026, granting Philip Morris International (PMI) the authority to market 20 variants of its Zyn nicotine pouch products with a specific, scientifically backed modified-risk claim. The federal agency ruled that using Zyn instead of traditional cigarettes lowers an individual’s risk of developing several devastating, smoking-related conditions, including mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. This decision marks the first time a nicotine pouch product has ever received a Modified Risk Tobacco Product (MRTP) designation in the United States, a move that public health experts believe could dramatically reshape how alternative nicotine delivery systems are communicated to the nation’s estimated 28 million adult smokers.
The FDA’s action does not represent a blanket endorsement, nor does it mean the pouches are considered entirely safe. Rather, it signifies that after an extensive, population-level scientific review, the agency concluded that the benefits of allowing adult smokers to learn about less harmful alternatives outweigh the potential risks, such as youth initiation. Under the Tobacco Control Act, the FDA permits these specialized marketing claims only when a manufacturer demonstrates that a product, as it is actually used by consumers, will significantly reduce harm and the risk of tobacco-related disease to individual users and benefit the health of the population as a whole.
The Shift to Modified-Risk Marketing
To understand the weight of this ruling, it helps to look at the timeline of Zyn’s regulatory path. In January 2025, the FDA granted Premarket Tobacco Product Applications (PMTAs) for these same 20 Zyn formulations, which officially authorized their commercial sale in the U.S. based on a baseline determination that they were “appropriate for the protection of public health.” However, that initial clearance did not allow PMI’s U.S. unit, Swedish Match USA, to make any health-related claims in its advertising.
The June 30 milestone elevates Zyn into a highly exclusive tier of tobacco and nicotine products. The new MRTP order explicitly authorizes the company to feature specific risk-reduction language directly on packaging and marketing materials.
In a public statement, Bret Koplow, Ph.D., J.D., acting director of the FDA’s Center for Tobacco Products (CTP), emphasized that the decision is rooted in transparency.
“FDA’s review of modified risk products is intended to ensure that adult users have clear, science-based information about the relative harms of tobacco products, so they can make informed choices,” Koplow stated. “Today’s decision allows these products to be marketed with a modified risk claim that informs adults who smoke about the lower risks associated with these products.”
Evaluating the Clinical Evidence
Nicotine pouches like Zyn are small, pre-portioned pouches containing nicotine pharmaceutical salts, flavorings, and plant-based fibers. Unlike traditional chewing tobacco or moist snuff, they do not contain actual tobacco leaf matting. Users place the pouch between their upper lip and gum, where nicotine is absorbed orally. Because there is no combustion—meaning no burning of tobacco, inhaling of smoke, or creation of tar and carbon monoxide—the chemical profile of the vaporless pouch is vastly simplified.
The FDA’s scientific review confirmed that Zyn pouches expose users to substantially lower amounts of Harmful and Potentially Harmful Constituents (HPHCs) than traditional cigarettes and even standard smokeless tobacco options.
Beyond laboratory toxicology reports, the FDA examined clinical data detailing how adults actually use the product. The data submitted by PMI revealed highly encouraging behavioral shifts among participants:
-
Complete Cessation: More than half (57.2%) of adult smokers who transitioned to Zyn reported zero cigarette consumption within the prior 30 days.
-
Harm Reduction: Among those who did not quit cigarettes entirely, a striking 80.7% significantly reduced their daily cigarette intake.
Public Health Pragmatism vs. Absolute Risk
For public health authorities, the Zyn ruling highlights a long-standing philosophical divide over harm reduction. The core dilemma centers on whether it is better to advocate for absolute nicotine abstinence or to offer heavily addicted smokers a “halfway house” that satisfies their chemical dependency without exposing their lungs to toxic smoke.
Supporters of the FDA’s decision, including researchers at the R Street Institute, argue that withholding risk-gradient information from smokers does a disservice to public health. They view the MRTP order as an essential tool for helping smokers make informed, incremental health improvements.
Conversely, agencies like the Centers for Disease Control and Prevention (CDC) maintain a more cautious baseline posture. The CDC regularly reminds the public that there is no such thing as a completely safe tobacco or nicotine product. Nicotine is an intensely addictive substance that can alter adolescent brain development, which continues up to roughly age 25. Furthermore, health authorities emphasize that the FDA has not evaluated or approved Zyn pouches as therapeutic smoking-cessation tools, such as nicotine patches or gums, which are designed to taper users off nicotine entirely.
Independent health researchers not affiliated with the study also urge caution regarding consumer perception. Stanton Glantz, Ph.D., a prominent tobacco control researcher at the University of California, San Francisco (UCSF), raised concerns that the “less harmful” label could backfire if it is misinterpreted by the public as an endorsement of safety, or if it inadvertently encourages non-smokers to pick up the habit.
The Youth Epidemic Guardrails
The primary risk factoring into the FDA’s population-health equation is youth uptake. The allure of flavored nicotine products to teenagers remains a critical battleground.
According to data from the 2024 National Youth Tobacco Survey cited during the review, roughly 1.8% of U.S. middle and high school students reported current use of nicotine pouches. While federal regulators currently consider this percentage relatively low—especially compared to the heights of the youth e-cigarette epidemic—public health advocates remain highly vigilant. Notably, the FDA’s modified-risk marketing order covers traditional varieties like Cool Mint, Spearmint, Wintergreen, Citrus, Coffee, and Cinnamon, but it deliberately excludes exotic or overly fruity flavors that are heavily favored by minors.
Matthew Farrelly, Ph.D., director of the Office of Science within the FDA’s CTP, clarified that the agency’s population-health judgment is conditional. The FDA is requiring Swedish Match USA to conduct rigorous, ongoing post-market surveillance to monitor how consumers perceive the new packaging claims and to watch for any spikes in youth initiation. Brian King, Ph.D., M.P.H., the director of the CTP, re-emphasized that the agency possesses the full legal authority to suspend or entirely withdraw the marketing order if youth uptake begins to trend upward.
What This Means for Consumers
For the everyday consumer, the practical message of the FDA’s ruling depends entirely on their current tobacco use status:
-
For Chronically Addicted Adult Smokers: The decision provides clear, federally verified assurance that switching completely from combustible cigarettes to Zyn nicotine pouches will reduce exposure to lethal toxins and lower the long-term risk of cardiovascular and respiratory diseases.
-
The Danger of Dual Use: Health professionals stress that “dual use”—smoking cigarettes while occasionally using pouches in smoke-free zones—does not deliver these health benefits. To lower disease risk, a total break from combustion is required.
-
For Non-Smokers, Teens, and Pregnant Women: The medical guidance remains absolute: do not start using these products. Nicotine causes rapid physical dependency and carries cardiovascular risks, and the long-term health consequences of using nicotine pouches for decades remain unknown.
As this new marketing hits shelves, public health agencies will be watching closely to see if the American public can successfully balance the nuance of a product that is undeniably “less harmful,” yet fundamentally unsafe.
References
- https://www.reuters.com/business/healthcare-pharmaceuticals/fda-allow-zyn-market-nicotine-pouches-less-harmful-than-cigarettes-axios-reports-2026-06-30/
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
